Close Menu

NEW YORK (GenomeWeb) — NeoGenomics disclosed last week that it has been ordered to pay Health Discovery $6.6 million by an arbitration panel handling a dispute between the erstwhile partners.

In early 2012, Health Discovery licensed certain biomarker-based testing tools for hematopoietic and solid tumor cancers to NeoGenomics for the development and commercialization of laboratory-developed tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.